Table 6.

Change from baseline in 6MWD (optional assessment)

Timepoint	Full analysis set		Switched patientsa		Treatment-naïve patients
	n	Change from baseline (mean ± SD), m	n	Change from baseline (mean ± SD), m	n	Change from baseline (mean ± SD), m
Dose-adjustment phase
Week 2	75	+20 ± 42	22	+8 ± 48	53	+25 ± 38
Week 4	77	+34 ± 39	19	+36 ± 31	58	+34 ± 42
Week 6	72	+41 ± 49	20	+30 ± 39	52	+45 ± 53
Week 8	93	+30 ± 70	21	+26 ± 47	72	+31 ± 76
Maintenance phase
Week 12	130	+33 ± 42	32	+28 ± 39	98	+34 ± 43
Week 24	105	+30 ± 63	20	+32 ± 45	85	+29 ± 67
Week 36	93	+32 ± 59	24	+37 ± 44	69	+31 ± 64
Week 48	62	+42 ± 60	13	+36 ± 68	49	+43 ± 59

6MWD 6-min walking distance, ERA endothelin receptor antagonist, PDE5 phosphodiesterase type 5, SD standard deviation

^aPatients who previously received an ERA, prostacyclin, and/or PDE5 inhibitor, and who stopped this treatment before starting riociguat